House passes AHA-supported bills to promote generic drug competition
The House of Representative today passed two AHA-supported bills to promote generic and biosimilar competition in the prescription drug market. The Orange Book Transparency Act (H.R. 1503) and Purple Book Continuity Act (H.R. 1520) would increase the accuracy and transparency of the two databases that guide development decisions for generic and biosimilar manufacturers.
Related News Articles
Headline
The AHA Dec. 11 expressed support for the reintroduction of the Future Advancement of Academic Nursing, bicameral legislation that would increase nursing…
Headline
The Centers for Medicare & Medicaid Services released guidance Dec. 8 for states implementing Medicaid community engagement requirements outlined by the…
Headline
The Trump administration announced a trade agreement with the U.K. Dec. 1 on pharmaceuticals that exempts U.K. drug products from Section 232 tariffs. In…
Headline
The Centers for Medicare & Medicaid Services Nov. 25 announced lower prices for 15 Medicare Part D drugs selected for the second cycle of negotiations…
Perspective
Imagine a powerful practice that strengthens human connection, improves well-being, boosts psychological health and supports a healthy workplace culture. And…
Headline
The Centers for Medicare & Medicaid Services Nov. 14 released preliminary guidance to states on implementing provider tax provisions in the One Big…